The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Aerie Pharmaceuticals, Inc. | COM | 00771V108 | 36,289 | 1,501,400 | SH | SOLE | 1,501,400 | 0 | 0 | ||
Arbutus BioPharma Corp. | COM | 03879J100 | 10,300 | 3,705,128 | SH | SOLE | 3,705,128 | 0 | 0 | ||
Alector, Inc. | COM | 014442107 | 6,090 | 353,462 | SH | SOLE | 353,462 | 0 | 0 | ||
Ascendis Pharma A/S | SPONSORED ADR | 04351P101 | 9,597 | 68,981 | SH | SOLE | 68,981 | 0 | 0 | ||
CymaBay Therapeutics, Inc. | COM | 23257D103 | 4,537 | 2,315,016 | SH | SOLE | 2,315,016 | 0 | 0 | ||
Cytokinetics Incorporated | COM NEW | 23282W605 | 25,453 | 2,398,970 | SH | SOLE | 2,398,970 | 0 | 0 | ||
Fulcrum Therapeutics, Inc. | COM | 359616109 | 24,960 | 1,500,000 | SH | SOLE | 1,500,000 | 0 | 0 | ||
Insmed Incorporated | COM | 457669307 | 34,137 | 1,429,518 | SH | SOLE | 1,429,518 | 0 | 0 | ||
Kura Oncology, Inc. | COM | 50127T109 | 935 | 68,000 | SH | SOLE | 68,000 | 0 | 0 | ||
The Medicines Company | COM | 584688105 | 34,249 | 403,217 | SH | SOLE | 403,217 | 0 | 0 | ||
Myokardia, Inc. | COM | 62857M105 | 18,977 | 260,370 | SH | SOLE | 260,370 | 0 | 0 | ||
OptiNose, Inc. | COM | 68404V100 | 8,028 | 870,766 | SH | SOLE | 870,766 | 0 | 0 | ||
SI-BONE, Inc. | COM | 825704109 | 6,626 | 308,183 | SH | SOLE | 308,183 | 0 | 0 | ||
Voyager Therapeutics, Inc. | COM | 92915B106 | 11,586 | 830,565 | SH | SOLE | 830,565 | 0 | 0 |